1. Home
  2. GMTL vs IPSC Comparison

GMTL vs IPSC Comparison

Compare GMTL & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardian Metal Resources PLC ADS

GMTL

Guardian Metal Resources PLC ADS

N/A

Current Price

$13.54

Market Cap

369.4M

ML Signal

N/A

Logo Century Therapeutics Inc.

IPSC

Century Therapeutics Inc.

N/A

Current Price

$2.23

Market Cap

362.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GMTL
IPSC
Founded
2021
2019
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Metal Mining
Medicinal Chemicals and Botanical Products
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
369.4M
362.5M
IPO Year
2024
2021

Fundamental Metrics

Financial Performance
Metric
GMTL
IPSC
Price
$13.54
$2.23
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$30.00
$4.25
AVG Volume (30 Days)
187.6K
506.9K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.30
EPS
N/A
N/A
Revenue
N/A
$109,164,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1556.76
52 Week Low
$8.60
$0.44
52 Week High
$22.21
$2.97

Technical Indicators

Market Signals
Indicator
GMTL
IPSC
Relative Strength Index (RSI) 59.18 59.12
Support Level $12.35 $2.13
Resistance Level $13.82 $2.39
Average True Range (ATR) 0.94 0.09
MACD 0.15 0.04
Stochastic Oscillator 82.28 95.83

Price Performance

Historical Comparison
GMTL
IPSC

About GMTL Guardian Metal Resources PLC ADS

Guardian Metal Resources PLC focuses on metals exploration and development, with a focus on precious metals exploration in North America. The Company has one business segment, which is the exploration and evaluation of mineral resources in Nevada, USA. Its exploration projects comprise the Pilot Mountain Project, Tempiute Project, Golconda Summit Project, Stonewall Project, and Garfield Project, and the Group is the operator of the Golconda Summit Project.

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.

Share on Social Networks: